Search

Your search keyword '"Klinker H"' showing total 503 results

Search Constraints

Start Over You searched for: Author "Klinker H" Remove constraint Author: "Klinker H"
503 results on '"Klinker H"'

Search Results

1. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

2. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

3. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

4. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

5. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

7. Health related quality of life of patients in opioid substitution therapy at the beginning of hepatitis C treatment - Data from the German Hepatitis C-Registry

10. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

11. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

14. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

22. Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial

25. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R)

26. Evolution of hepatitis C virus genotype 1a vs. 1b distribution reflects profound changes of HCV epidemiology in Germany between 2004 and 2018 - Analysis of 17,093 patients from five consecutive registries including the German Hepatitis C-Registry (DHC-R)

36. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs – Results from the German Hepatitis C-Registry (DHC-R)

37. High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R)

38. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

39. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R)

41. Der Einfluss des Alanin-Aminotransferase (ALT)-Verlaufs auf die Krankheitsprogression bei Patienten mit chronischer Hepatitis B e Antigen (HBeAg)-negativer Infektion: 4 Jahres-Daten einer prospektiven longitudinalen Studie (ALBATROS Studie)

42. High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R)

44. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial

45. Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

46. Prävalenz von HCV NS5A Resistenzen und Therapieansprechen bei DAA-naiven Patienten mit einer chronischen Genotyp (GT) 1a Hepatitis C Virusinfektion

47. Hinzunahme von pegyliertem-Interferon-alpha zu einer bestehenden Nukleos(t)id-Analoga Therapie der HBeAg negativen Hepatitis B: Ergebnisse der prospektiven PADD-ON Studie

49. Therapie der Hepatitis C in Deutschland. Ergebnisse aus dem Deutschen Hepatitis C-Register 4 Jahre nach Zulassung der neuen direkt-antiviralen Substanzen (DAAs)

50. Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R)

Catalog

Books, media, physical & digital resources